Ligand Pharmaceuticals (NASDAQ:LGND) Lowered to Sell Rating by StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. A number of other equities research analysts have also commented on the company. Benchmark reiterated a “buy” rating and issued a $135.00 target price on […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. A number of other equities research analysts have also commented on the company. Benchmark reiterated a “buy” rating and issued a $135.00 target price on […]